EUVIMEDEUVIMED entdecken
Crossref

Anti-tumor potential of combinatory GSK3 inhibition in human 3D models of pancreatic neuroendocrine tumors and patient-derived GEP-NET primary cultures

Svenja Nölting, Edlira Luca iD, Igor Shapiro, Katharina Wang iD, Christoph J Auernhammer, Felix Beuschlein, Kathrin Zitzmann, Huguette Debaix, Constanze Hantel iD

Endocrine-Related Cancer · 2025

DOI: 10.1530/erc-25-0073 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Svenja Nölting und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zürich, Switzerland. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neuroendocrine Tumors, Glycogen Synthase Kinase 3, Stomach Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activation of signaling pathways that regulate survival, proliferation, motility, inflammation, metabolism, and stemness fuel tumor growth, metastasis, and recurrence. Therapies targeting signaling pathway components, including candidates such as GSK3 and TNFα, drastically affect cellular viability in preclinical cancer models but have limited success in the clinic. However, in recent years, spheroids and organoids have been demonstrated to more accurately reflect tumor characteristics and to be better predictors of therapeutic response than monolayer cultures. Here, we used 3D models from the pancreatic neuroendocrine tumor (pNET) model BON1 to evaluate the effect of GSK3 inhibition along with TNFα or insulin and extended our results in primary gastroenteropancreatic (GEP-)NET culture. The multidimensional configuration of BON1 spheroids imparted aggressive characteristics and a lack of anti-proliferative effects upon single treatments. However, GSK3 inhibition alone resulted in dispersion of spheroids, indicating that GSK3 is necessary for cell–cell adhesions and participates in spheroid architecture. Interestingly, GSK3 inhibition in combination with TNFα or insulin led to drastically reduced cell proliferation. In fresh patient-derived 2D primary cultures from (GEP-)NETs, we demonstrate that insulin has tumor-promoting effects, while GSK3 inhibition and metformin display significant anti-tumor activity mediated through common effects on GSK3/insulin signaling. Both agents show strong efficacy in a patient-derived insulinoma without affecting the corresponding normal pancreatic tissue. We conclude that treatment efficacy depends on three-dimensional architecture and that combinatorial treatments which target cellular dispersion in addition to cellular viability might have beneficial clinical applications, but metastatic potential of remaining single cells needs further characterization before clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsNeuroendocrine TumorsGlycogen Synthase Kinase 3Stomach NeoplasmsIntestinal NeoplasmsProtein Kinase InhibitorsHumansSpheroids, CellularTumor Cells, CulturedCell ProliferationTumor Necrosis Factor-alphaInsulin

Stichwörter der Autor:innen

BON1GSK3TNFαWnt/β-cateningastroenteropancreatic (GEP-)NETsinsulinpancreatic neuroendocrine tumorspheroids

Substanzen

Glycogen Synthase Kinase 3Tumor Necrosis Factor-alphaInsulinProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zürich, Switzerland.
  • Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
  • ENETS Center of Excellence Zurich, University Hospital Zurich, Zürich, Switzerland.
  • Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS Center of Excellence), LMU University Hospital, LMU Munich, Munich, Germany.
  • The LOOP Zurich-Medical Research Center, Zurich, Switzerland.

ORCID-Profile: Edlira Luca, Katharina Wang, Constanze Hantel

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Nölting, S., Luca, E., Shapiro, I., Wang, K., Auernhammer, C. J., Beuschlein, F., Zitzmann, K., Debaix, H., & Hantel, C. (2025). Anti-tumor potential of combinatory GSK3 inhibition in human 3D models of pancreatic neuroendocrine tumors and patient-derived GEP-NET primary cultures. Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0073

Vancouver

Nölting S, Luca E, Shapiro I, Wang K, Auernhammer CJ, Beuschlein F, et al. Anti-tumor potential of combinatory GSK3 inhibition in human 3D models of pancreatic neuroendocrine tumors and patient-derived GEP-NET primary cultures. Endocrine-Related Cancer. 2025. doi:10.1530/erc-25-0073

BibTeX
@article{Nlting2025,
  author = {Nölting, Svenja and Luca, Edlira and Shapiro, Igor and Wang, Katharina and Auernhammer, Christoph J and Beuschlein, Felix and Zitzmann, Kathrin and Debaix, Huguette and Hantel, Constanze},
  title = {Anti-tumor potential of combinatory GSK3 inhibition in human 3D models of pancreatic neuroendocrine tumors and patient-derived GEP-NET primary cultures},
  journal = {Endocrine-Related Cancer},
  year = {2025},
  doi = {10.1530/erc-25-0073}
}
Kostenlos starten →